Latest period
$71.56M
YoY change
+71.2%
5Y CAGR
-3.6%
Peak year (2019)
$140.16M
Cumulative CapEx
$915.03M
CapEx history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: $58.70M
CapEx growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: +71.2%
CapEx history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| 2025 | $58.70M | +71.2% | +$24.42M | ||
| 2024 | $34.28M | -44.9% | −$27.93M | ||
| 2023 | $62.21M | -13.7% | −$9.85M | ||
| 2022 | $72.06M | -5.6% | −$4.31M | ||
| 2021 | $76.37M | +8.5% | +$6.01M | ||
| 2020 | $70.36M | -49.8% | −$69.80M | ||
| 2019 | $140.16M | +10.5% | +$13.27M | ||
| 2018 | $126.89M | +21.8% | +$22.68M | ||
| 2017 | $104.21M | +61.4% | +$39.65M | ||
| 2016 | $64.56M | +398.5% | +$51.61M | ||
| 2015 | $12.95M | +44.5% | +$3.99M | ||
| 2014 | $8.96M | +123.7% | +$4.96M | ||
| 2013 | $4.01M | -52.0% | −$4.34M | ||
| 2012 | $8.35M | +546.6% | +$7.06M | ||
| 2011 | $1.29M | -72.7% | −$3.44M | ||
| 2010 | $4.73M | -4.4% | −$217.00K | ||
| 2009 | $4.95M | -54.0% | −$5.82M | ||
| 2008 | $10.76M | +38.2% | +$2.98M | ||
| 2007 | $7.79M | +56.2% | +$2.80M | ||
| 2006 | $4.99M | +156.1% | +$3.04M | ||
| 2005 | $1.95M | -78.4% | −$7.06M | ||
| 2004 | $9.01M | +188.7% | +$5.89M | ||
| 2003 | $3.12M | +455.0% | +$2.56M | ||
| 2002 | $562.00K | — | — |
- 2025$58.70M+71.2%
- 2024$34.28M-44.9%
- 2023$62.21M-13.7%
- 2022$72.06M-5.6%
- 2021$76.37M+8.5%
- 2020$70.36M-49.8%
- 2019$140.16M+10.5%
- 2018$126.89M+21.8%
- 2017$104.21M+61.4%
- 2016$64.56M+398.5%
- 2015$12.95M+44.5%
- 2014$8.96M+123.7%
- 2013$4.01M-52.0%
- 2012$8.35M+546.6%
- 2011$1.29M-72.7%
- 2010$4.73M-4.4%
- 2009$4.95M-54.0%
- 2008$10.76M+38.2%
- 2007$7.79M+56.2%
- 2006$4.99M+156.1%
- 2005$1.95M-78.4%
- 2004$9.01M+188.7%
- 2003$3.12M+455.0%
- 2002$562.00K—
CapEx values are taken from Alnylam Pharmaceuticals's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current CapEx (TTM) is $71.56M. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Alnylam Pharmaceuticals (ALNY) most recent annual CapEx stands at $58.70M (2025) – surged 71.2% year-over-year.
Alnylam Pharmaceuticals CapEx compound annual growth for the 2020–2025 (5 years) window is -3.6%, with a net decline across the window.
Between 2019 and 2025, Alnylam Pharmaceuticals CapEx plunged 58.1%, falling from $140.16M to $58.70M.
The record annual CapEx stands at $140.16M, reached in 2019; the historical low of $562.00K was recorded in 2002.
Alnylam Pharmaceuticals Capital Expenditures by Year
Alnylam Pharmaceuticals Capital Expenditures 2025: $58.70M
Alnylam Pharmaceuticals CapEx in 2025 was $58.70M, surged 71.2% from 2024.
Alnylam Pharmaceuticals Capital Expenditures 2024: $34.28M
2024's CapEx for Alnylam Pharmaceuticals came in at $34.28M, plunged 44.9% below 2023.
Alnylam Pharmaceuticals Capital Expenditures 2023: $62.21M
Alnylam Pharmaceuticals posted CapEx of $62.21M in 2023, declined 13.7% below 2022.
Alnylam Pharmaceuticals Capital Expenditures 2022: $72.06M
In 2022, Alnylam Pharmaceuticals reported CapEx of $72.06M, declined 5.6% below 2021.
Alnylam Pharmaceuticals Capital Expenditures 2021: $76.37M
Alnylam Pharmaceuticals CapEx in 2021 was $76.37M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by CapEx
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation